5. References

- ICH Q2 (R1): (2005), Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use, ICH Harmonized Tripartite Guideline.

- BCCA Drug Monograph: Busulfan. The Cancer Drug Manual. Vancouver.

- Product Monograph: (May 2008) Busulfex® (Busulfan IV). Otsuka Pharmaceutical.

- Product Monograph: (July 2004) Myleran® (Busulfan PO). Glaxo Smith Kline Inc.

- Busulfan (2004), AHFS Drug information

- Busulfan, Drugdex® - Micromedex Healthcare Series.

- Eberly AL, Anderson GD, Bubalo JS et al (2008). Optimal Prevention of Seizures Induced by High- Dose Busulfan. Pharmacotherapy, 28(12):1502–10.

- Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, National Institutes of Health; 1983. US Department of Health and Human Services, Public Health Service publication NIH 83-2621.

- AMA Council on Scientific Affairs (1985), Guidelines for handling parenteral antineoplastic. *JAMA,* 253:1590-1591.

- Hassan M, Oberg G, Bjiirkholm M (1993). Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol, 33:181 – 186

- Clinical Oncology Society of Australia (1983), Guidelines and recommendations for safe handling of antineoplastic agents. *Med J Australia,* 1:426- 428.

- Warwick GP (1963). The mechanism of action of alkylating agents,23:1315-33.
- Feit PW, Rastrup-Andersen N (1973). 4-Methanesulfonyloxybutanol: hydrolysis of Busulfan. J Pharm Sci, 62:1007-8.
- Haddow A, Timmis GM (1953), Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet, 264:207-8.
- Santos G, Tutschka P, Brookmeyer R et al (1983) Marrow transplantation for acute onlymphocytic leukemia after treatment with Busulfan & cyclophosphamide. N Engl J Med, 309:1347-53.
- Tutschka PJ, Copelan EA, Klein JP(1987) Bone marrow transplantation for leukaemia following a new Busulfan and cyclophosphamide regimen. Blood,70:1382-8.
- Hassan M, Öberg G, Ehrsson H et al (1989) Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol,36:525-30.
- Vassal G, Gouyette A, Hartmann O et al (1989) Pharmacokinetics of high-dose Busulfan in children. Cancer Chemother Pharmacol, 24:386-90.
- Bhagwatwar HP, Phadungpojna S, Chow DS-L, Andersson BS (1996) Formulation and stability of Busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol,37:401-8.
- Andersson BS, Madden T, Tran HT et al (2000), Acute safety and pharmacokinetics of intravenous Busulfan when used with oral Busulfan & cyclophosphamide as pretransplantation conditioning therapy. Blood Marrow Transplant, 6:548-54.

- Andersson BS, Kashyap A, Gian V et al (2002) Conditioning therapy with intravenous Busulfan, cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant, 8:145-54.

- Eberly AL, Anderson GD, Bubalo JS et al (2008) Optimal Prevention of Seizures Induced by High-Dose Busulfan. Pharmcotherapy, 28(12):1502–10**.**

- National Study Commission on Cytotoxic Exposure (1987), Recommendations for handling cytotoxic agents. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA, 02115.

- Jones RB, Frank R, Mass T (1983), Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. *CA-A Cancer J for Clin,* 33:258-263.

- American Society of Hospital Pharmacists (1990), ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. *Am J Hosp Pharm,*47:1033-1049.

- Davidson AG (2002), Ultraviolet-Visible absorption spectrophotometry. In Beckett AH, Stenlake JB, editors. Practical Pharmaceutical Chemistry. 4th Ed. Part-2. New Delhi: CBS Publishers; p. 275-300.

- Ewing GW (1985) Instrumental Methods of Chemical Analysis; 5th Edn; McGraw-Hill Book Company, New York, pp 1-7.

- Satoskar R S, Bhandarkar S D, Ainapure S S (2003) “Pharmacology and Pharmacotherapeutics”, 16th edition, Mumbai: Popular prakashan, 401- 06.

- IUPAC Nomenclature for Chromatography, IUPAC Recommendations 1993, Pure & Appl. Chem., 1993, 65(4):819-872.

- Still W C, Kahn M, Mitra A, J. Org. Chem. 1978, 43(14):2923-2925
- Martin A. J. P and Synge R. L. M, Biochem J., 1941, 35:1358.
- Scott Raymond P. W, Principles and Practice of Chromatography, Chrom-Ed Book Series, 01-02, www.library4science.com.
- www.rpi.edu/dept/chem-eng/biotech-eron/chromo/be_types.htm
- www.chem.neu.edu/courses/1221/PAM/chromatogr/index.htm
- www.wikipedia.com,wikipedia, free encyclopedia.
- National Gallery of Art Conservation (2007), Scientific Research, www.nga.gov, P,08-21.
- Rivat C and Stoltz J. F (1993), Biotechnology of Blood Proteins-Purification, Clinical and Biological Applications.
- Bailly M. and Nicoud R. M, (LSGC-ENSIC, 1, rue Grandville, 54001 Nancy and SEPAREX, 5, rue Monod, 54250, Champigneulle, France): The simulated moving bed: a powerful process for purification.
- Van Deemter, Zuiderweg E J, Klinkenberg A (1956), Longitudinal diffusion and resistance to mass transfer as causes of non ideality in chromatography. Chem. Eng. Sci, 5: 271-289.
- Srivastava B, Sharma B. K, Baghel U. S, Ultra performance liquid chromatography (UPLC): a chromatography technique, International Journal of Pharmaceutical Quality Assurance, 2(1): 19-25.